Kite, Juno, and BlueBird will give updates on T-cell therapies.
The only KM event expressly for the Life Sciences
Company aims to hit 5% growth every year
Immunotherapy combinations will be the focus – but attention is shifting towards these agents proving their overall survival benefits.
Drug gets fast review in tough to treat follicular lymphoma
Watson will be used to improve prevention of Substance Use Disorder relapses.
Trump’s FDA pick also vows to take on opioid addiction crisis
Company still in race to develop CGRP inhibitor for migraine.